JAK2V617F mutation in patients with thrombosis: to screen or not to screen?
- 1 December 2010
- journal article
- review article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 33 (2), 117-124
- https://doi.org/10.1111/j.1751-553x.2010.01275.x
Abstract
Thrombotic complications are a main concern in patients with myeloproliferative neoplasms. Recently, a gain-of-function mutation of the gene encoding the JAK2 tyrosine kinase that results in a valine-to-phenylalanine substitution at position 617 (V617F) has been described. Since the description of the JAK2-V617F mutation and its finding in patients with splanchnic vein thrombosis without an overt myeloproliferative neoplasm, many groups have studied the prevalence of this mutation in patients with unexplained venous and arterial thrombosis. A literature search was made using the key words thrombosis, JAK2V617F mutation, myeloproliferative neoplasms, cerebral vein thrombosis and splanchnic vein thrombosis. JAK2V617F is frequent in patients with splanchnic vein thrombosis, but is rare in patients with venous thrombosis at other locations or with arterial thrombosis. Routine testing for JAK2V617F is not currently recommended for patients with unexplained thromboses, except for those with splanchnic vein thrombosis. In patients with cerebral vein thrombosis, the value of testing for JAK2V617F mutation is yet to be established.Keywords
This publication has 61 references indexed in Scilit:
- Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like diseaseBlood, 2010
- JAK2V617F Mutation in Patients with Portal Vein ThrombosisDigestive Diseases and Sciences, 2008
- ClinicalJAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locationsAmerican Journal of Hematology, 2008
- The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorderThrombosis and Haemostasis, 2008
- JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosisBlood, 2007
- Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patientsLeukemia, 2007
- Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyThe Lancet, 2005
- Clinical implications of the JAK2 V617F mutation in essential thrombocythemiaLeukemia, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemiaAnnals of Hematology, 1999